Cat. #153252
K562 AZQR Cell Line
Cat. #: 153252
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Organism: Human
Tissue: Lymphatic Tissue
Disease: Cancer
Model: Tumour line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Timothy Ward
Institute: Cancer Research UK Manchester Institute
Tool Details
*FOR RESEARCH USE ONLY
- Name: K562 AZQR Cell Line
- Tool sub type: Continuous
- Parental cell: K562
- Organism: Human
- Tissue: Lymphatic Tissue
- Disease: Cancer
- Growth properties: Suspension
- Model: Tumour line
- Conditional: No
- Description: The cells have been shown to contain decreased levels of glutathione and superoxoid dismutase. They are cross-resistant to adriamycin, mitzolamide, MMNG and mitmycin. Cells should be challenged with AZQ at every 4th passage at a minimum density of 100,000 cells/ml. It is recommended to cultivate the cells without drug on resuscitation.
- Production details: The drug resistant cell line K562 AZQ was developed from the parent K562 cell line by treatment with AZQ C215-bis (carboethoxyamino)-3, 6-diazitinyl 1;4 (benzoquinone).
- Cellosaurus id: CVCL_2967
Handling
- Format: Frozen
- Growth medium: Subculture Routine: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37?°C.Culture Medium: RPMI 1640 + 10% Foetal Bovine Serum (FBS) + 2mM Glutamine. Challenge with 1 mM AZQ every 4th passage.
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
References
- Ward et al. 1995. Biochem Pharmacol. 50(4):459-64. PMID: 7646550.
- Cross-resistance studies on two K562 sublines resistant to diaziridinylbenzoquinones.
